# Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-present-at-the-jefferies-global-healthcare-conference
Ticker: RLMD
Company: Relmada
Source: Relmada
Published: 2026-06-25 13:46 EST
Original Source URL: https://www.relmada.com
## Summary

CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a…...

## Article Body
May 28, 2026 7:00 AM EDT

CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.

Jefferies Global Healthcare Conference Details Format: Fireside Chat Date: Thursday, June 4, 2026 Time: 12:50 PM ET Webcast: Click Here

Management will also be available for one-on-one investor meetings during the conference. Please contact your Jefferies representative to schedule a meeting.

The webcast can also be accessed on the Events page of the Investors section of the Relmada website at https://www.relmada.com/for-investors/ir-calendar . An archived replay will be available for 90 days following the conclusion of the event.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact: Brian Ritchie LifeSci Advisors britchie@lifesciadvisors.com

Media Inquiries: Corporate Communications media@relmada.com

Source: Relmada Therapeutics

Released May 28, 2026
## Recent Company News
- 2026-07-16 11:05 EST — [Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-a5332b5c) — Source: Relmada
- 2026-06-29 11:00 EST — [Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-joins-russell-2000-and-russell-3000-indexes-f3211c84) — Source: Relmada
- 2026-06-25 13:46 EST — [Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-cns-drug-development-veteran-michael-quirk-as-senior-advisor-for-sepranolone-program) — Source: Relmada
- 2026-06-25 13:46 EST — [Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-present-at-the-jefferies-global-healthcare-conference) — Source: Relmada
- 2026-06-25 13:46 EST — [Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Relmada
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)